Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients
Abstract Background Dysbiosis of the gut microbiota can lead to impaired therapeutic effect of immune checkpoint inhibitors (ICIs). This study aimed to investigate the use of probiotics on the clinical outcomes of cancer patients receiving ICIs therapy. Method PubMed, EMBASE, and the Cochrane Librar...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4994 |
| _version_ | 1811176377806749696 |
|---|---|
| author | Luying Wan Chunlan Wu Qin Wu Shuimei Luo Junjin Liu Xianhe Xie |
| author_facet | Luying Wan Chunlan Wu Qin Wu Shuimei Luo Junjin Liu Xianhe Xie |
| author_sort | Luying Wan |
| collection | DOAJ |
| description | Abstract Background Dysbiosis of the gut microbiota can lead to impaired therapeutic effect of immune checkpoint inhibitors (ICIs). This study aimed to investigate the use of probiotics on the clinical outcomes of cancer patients receiving ICIs therapy. Method PubMed, EMBASE, and the Cochrane Library database were searched to retrieve relevant studies that exploring the relationship between probiotics and the efficacy of ICIs. The primary endpoints included overall survival (OS) and progression‐free survival (PFS), evaluated by the hazard rations (HRs) with 95% confidence intervals (CI), and the secondary endpoint was objective response rate (ORR), evaluated by the odd ratio (OR) with a 95% CI. Results A total of five studies including 1031 patients were eligible for analysis. Our results indicated that the use of probiotics was associated with a superior OS (HR = 0.50, 95% CI: 0.30–0.85, p = 0.01) and PFS (HR = 0.51, 95% CI: 0.42–0.61, p < 0.01), but had no relationship with ORR (OR = 2.11, 95%CI: 0.51–8.65, p = 0.30) in non‐small cell lung cancer (NSCLC) patients. Conclusions Probiotics were positively correlated with OS and PFS in NSCLC patients administrated with ICIs, but had no relationship with ORR. |
| first_indexed | 2024-04-10T19:51:31Z |
| format | Article |
| id | doaj.art-4490e3e38fd64704b933063a7e188600 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-10T19:51:31Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-4490e3e38fd64704b933063a7e1886002023-01-28T05:30:05ZengWileyCancer Medicine2045-76342023-01-011221841184910.1002/cam4.4994Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patientsLuying Wan0Chunlan Wu1Qin Wu2Shuimei Luo3Junjin Liu4Xianhe Xie5Department of Oncology The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian ChinaDepartment of Oncology The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian ChinaDepartment of Oncology The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian ChinaDepartment of Oncology The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian ChinaDepartment of Infectious Diseases The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian ChinaDepartment of Oncology The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian ChinaAbstract Background Dysbiosis of the gut microbiota can lead to impaired therapeutic effect of immune checkpoint inhibitors (ICIs). This study aimed to investigate the use of probiotics on the clinical outcomes of cancer patients receiving ICIs therapy. Method PubMed, EMBASE, and the Cochrane Library database were searched to retrieve relevant studies that exploring the relationship between probiotics and the efficacy of ICIs. The primary endpoints included overall survival (OS) and progression‐free survival (PFS), evaluated by the hazard rations (HRs) with 95% confidence intervals (CI), and the secondary endpoint was objective response rate (ORR), evaluated by the odd ratio (OR) with a 95% CI. Results A total of five studies including 1031 patients were eligible for analysis. Our results indicated that the use of probiotics was associated with a superior OS (HR = 0.50, 95% CI: 0.30–0.85, p = 0.01) and PFS (HR = 0.51, 95% CI: 0.42–0.61, p < 0.01), but had no relationship with ORR (OR = 2.11, 95%CI: 0.51–8.65, p = 0.30) in non‐small cell lung cancer (NSCLC) patients. Conclusions Probiotics were positively correlated with OS and PFS in NSCLC patients administrated with ICIs, but had no relationship with ORR.https://doi.org/10.1002/cam4.4994gut microbiomeimmune checkpoint inhibitorsobjective response rateoverall survivalprogression‐free survivalprobiotics |
| spellingShingle | Luying Wan Chunlan Wu Qin Wu Shuimei Luo Junjin Liu Xianhe Xie Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients Cancer Medicine gut microbiome immune checkpoint inhibitors objective response rate overall survival progression‐free survival probiotics |
| title | Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients |
| title_full | Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients |
| title_fullStr | Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients |
| title_full_unstemmed | Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients |
| title_short | Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients |
| title_sort | impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients |
| topic | gut microbiome immune checkpoint inhibitors objective response rate overall survival progression‐free survival probiotics |
| url | https://doi.org/10.1002/cam4.4994 |
| work_keys_str_mv | AT luyingwan impactofprobioticsuseonclinicaloutcomesofimmunecheckpointinhibitorstherapyincancerpatients AT chunlanwu impactofprobioticsuseonclinicaloutcomesofimmunecheckpointinhibitorstherapyincancerpatients AT qinwu impactofprobioticsuseonclinicaloutcomesofimmunecheckpointinhibitorstherapyincancerpatients AT shuimeiluo impactofprobioticsuseonclinicaloutcomesofimmunecheckpointinhibitorstherapyincancerpatients AT junjinliu impactofprobioticsuseonclinicaloutcomesofimmunecheckpointinhibitorstherapyincancerpatients AT xianhexie impactofprobioticsuseonclinicaloutcomesofimmunecheckpointinhibitorstherapyincancerpatients |